Related references
Note: Only part of the references are listed.Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
E. Alba et al.
ANNALS OF ONCOLOGY (2012)
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes
O. Humbert et al.
ANNALS OF ONCOLOGY (2012)
Neoadjuvant chemotherapy in ER+HER2-breast cancer: response prediction based on immunohistochemical and molecular characteristics
E. H. Lips et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Laura J. Esserman et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades
Reina Haque et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
Bhumsuk Keam et al.
BMC CANCER (2011)
St. Gallen 2011: Summary of the Consensus Discussion
Michael Gnant et al.
BREAST CARE (2011)
Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments
Ronald Boellaard
JOURNAL OF NUCLEAR MEDICINE (2011)
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
Jorma J. de Ronde et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy A Single Institutional Experience With 359 Cases
Rohit Bhargava et al.
CANCER (2010)
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
K. David Voduc et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
Seung Il Kim et al.
ONCOLOGY (2010)
Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting
Marco Colleoni et al.
BREAST (2009)
Variability and reproducibility of hepatic FDG uptake measured as SUV as well as tissue-to-blood background ratio using positron emission tomography in healthy humans
Inge-Lis Kanstrup et al.
CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING (2009)
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F] Fluorodeoxyglucose
Joerg Schwarz-Dose et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Standards for PET Image Acquisition and Quantitative Data Analysis
Ronald Boellaard
JOURNAL OF NUCLEAR MEDICINE (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani et al.
BREAST CANCER RESEARCH (2009)
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
Alina Berriolo-Riedinger et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Primary systemic chemotherapy of invasive lobular carcinoma of the breast
Artur Katz et al.
LANCET ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography
Caroline Rousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
MC Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
FDG uptake in breast cancer:: correlation with biological and clinical prognostic parameters
A Buck et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma:: comparison with biochemical determination in a prospective study of 793 cases
B Zafrani et al.
HISTOPATHOLOGY (2000)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
